Biogen Shares Sink as Slashed 2026 Profit Outlook Overshadows Q1 Earnings Beat
Biogen (BIIB) shares are under heavy pressure Thursday, sliding 3.33% to $187.90 as a significant cut to full-year earnings guidance soured investor sentiment following the company's first-quarter results. While the biopharmaceutical giant delivered a double-beat on the top and bottom lines, the market is focused on the roughly $1.00 per share reduction in profit outlook tied to recent acquisition costs and ongoing erosion in its legacy multiple sclerosis franchise.
Guidance Cut Rattles Investors
The primary driver behind today's sell-off is Biogen's revised 2026 non-GAAP diluted EPS guidance. The company now expects full-year earnings in the range of $14.25 to $15.25 per share, a sharp decrease from its previous forecast of $15.25 to $16.25. Management attributed this $1.00 reduction primarily to acquired in-process research and development (IPR&D) charges stemming from its aggressive business development strategy, most notably the $5.6 billion acquisition of Apellis Pharmaceuticals.
This downward revision caught the market off guard, as the new midpoint of $14.75 sits well below the prior analyst consensus of approximately $15.16. The move highlights the near-term financial "digestion" period required for Biogen's pivot toward rare diseases and immunology, even as it attempts to move past its aging multiple sclerosis (MS) portfolio. Investors are clearly penalizing the company for the immediate margin compression associated with these strategic deals.
Q1 Beat Fails to Provide Support
The plunge in share price comes despite a first quarter that, on the surface, appeared exceptionally strong. Biogen reported non-GAAP EPS of $3.57, crushing the $2.95 consensus estimate by 21%. Revenue also outperformed, coming in at $2.48 billion against expectations of $2.25 billion, representing a 2% year-over-year increase.
Growth products provided a rare bright spot in the report. Leqembi, the company’s high-profile Alzheimer’s treatment developed with Eisai, saw global in-market sales surge 74% year-over-year to $168 million, comfortably beating the $152 million expected by Wall Street. Similarly, Skyclarys revenue reached $151 million, up 22% and exceeding estimates. However, these gains were not enough to offset the broader concerns regarding the company's full-year trajectory and the continued decline of its legacy MS franchise, which saw revenues of $958 million as generic competition continues to erode market share.
Strategic Pivot and Market Divergence
Biogen's performance today stands in stark contrast to the broader market, with the stock trailing the S&P 500 by a staggering 4.30%. While the SPY gained 0.97% in a generally positive session, Biogen's idiosyncratic guidance issues made it a clear outlier. The high volume of 815.9K shares traded suggests significant institutional repositioning following the news.
Analysts remain divided on the stock's path forward. RBC Capital's Brian Abrahams maintained an "Outperform" rating and raised his price target to $222, citing "growing confidence in Biogen's potential to navigate the competitive landscape." Conversely, Wedbush maintained a "Neutral" stance with a $196 target, reflecting a more cautious view on the stock's near-term upside given the integration risks of the Apellis deal.
Looking ahead, investors will be closely watching the integration of Apellis and the May 24 FDA decision on a subcutaneous version of Leqembi, which could significantly expand patient access. While the Q1 "beat" suggests operational efficiency, the lowered bar for 2026 suggests that the transition to a post-MS growth story remains a costly and volatile endeavor for shareholders.
Key Takeaways
- Biogen lowered its 2026 non-GAAP EPS guidance range to $14.25–$15.25 from $15.25–$16.25, a $1.00 per share reduction.
- The guidance cut is tied to $1.00 per share in IPR&D charges related to the $5.6 billion acquisition of Apellis Pharmaceuticals.
- Q1 results beat expectations with $3.57 EPS on $2.48 billion in revenue, driven by strong Leqembi and Skyclarys sales.
- The stock is sharply underperforming the S&P 500 by 4.30% today as investors focus on near-term margin pressure over long-term pipeline potential.